The main objective of the present investigation was to evaluate the safety, tolerability and effect of the co-administration of EGF (epidermal growth factor) and GHRP-6 (growth hormone releasing peptide) at two dose levels, in the treatment of patients with Acute cerebral infarction in ischemic etiology. During the investigation, the safety and tolerability of the combination was determined through clinical adverse events, vital signs, and laboratory tests. The effect of co-administration in acute cerebral infarction was evaluated in terms of the reduction in capacity measured by the Rankin scale and death at discharge and 3 and 6 months after treatment, and the effect of co-administration was evaluated at the level of neurological deficit mediated by the NIHSS scale and in the ability to perform activities according to the Barthel index, at discharge and at 3 and 6 months post-treatment. The study covered the period from July 2017 to January 2018. The analysis of the frequency of adverse events allowed to corroborate, in terms of safety, that the co-administration of EGF + GHRP-6 is safe and tolerable. The pharmacological intervention with EGF + GHRP-6 was associated with a better neurological outcome in terms of disability reduction in patients who had more severe heart attacks. The results in terms of probabilities of beneficial effect and favorable neurological effects were consistent across all applied analyzes, which included evaluation by strata and globally. The Pharmacological intervention with EGF + GHRP-6 in patients with cerebral infarction was associated with a longer and significant survival.